The differential diagnosis of dyshidrosis includes pustular psoriasis of the palms and soles, chronic vesicular hand dermatitis contact allergy, vesicular tinea pedis and tinea manus, scabies ...

Dads and daughters get mani-pedis at South Hills nail salon An out-of-the-box bonding experience brought together some doting daughters and their dedicated dads ahead of the Father's Day weekend.

The approval is based on results from the pivotal ADEPT phase 2/3 study. Patients with moderate-to-severe bullous pemphigoid were randomly assigned to receive Dupixent 300 mg (53 individuals) or ...

The FDA approved Dupixent for the treatment of adults with bullous pemphigoid, a rare skin disease often uncontrolled with systemic corticosteroids, Sanofi and Regeneron announced. The FDA’s ...

Dupilumab, administered by subcutaneous injection, is the first targeted treatment to be approved in the United States for bullous pemphigoid, according to the company’s press release.

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid (BP), a condition that predominantly ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that largely affects elderly patients, drugmakers Sanofi and Regeneron ...

Spongiotic dermatitis describes skin inflammation that causes swelling, redness, and itching. It's most often associated with atopic dermatitis or eczema.

Sanofi & Regeneron’s Dupixent receives US FDA approval to treat patients with bullous pemphigoid Paris Saturday, June 21, 2025, 12:00 Hrs [IST] The US Food and Drug Administration (FDA) has approved ...